Search our Database of Scientific Publications and Authors

I’m looking for a

    505 results match your criteria Cutaneous CD30+ Ki-1 Anaplastic Large-Cell Lymphoma

    1 OF 11

    A rare localised nasal CD30(+) primary cutaneous T-cell lymphoma following liver transplantation.
    BMJ Case Rep 2017 Nov 4;2017. Epub 2017 Nov 4.
    Scripps Clinic, Scripps Center for Organ Transplantation, La Jolla, California, USA.
    Cutaneous T-cell post-transplant lymphoproliferative disorder (PTLD) is a rare clinical presentation that can potentially turn aggressive in solid-organ transplant recipients if not detected and intervened on early. We encountered a rare case of rapidly worsening primary cutaneous CD30-positive, Epstein-Barr virus-negative anaplastic large cell lymphoma (ALCL) of T-cell origin, manifesting as an isolated nasal tip lesion in a 71-year-old man 4 years after orthotopic liver transplantation. Excisional biopsy with partial rhinectomy showed subepithelial diffuse infiltration of medium-to-large lymphoid cells having round-to-irregular nuclei, partially condensed chromatin and prominent nucleoli. Read More

    The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: Are we there yet?
    Br J Dermatol 2017 Oct 10. Epub 2017 Oct 10.
    Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA.
    Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate that is approved for refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. In the ALCANZA trial, the proportion of CD30+ cutaneous T-cell lymphoma (CTCL) patients achieving an objective response lasting at least 4 months was 56.3% with BV versus 12. Read More

    Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
    South Asian J Cancer 2017 Jul-Sep;6(3):129-131
    Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
    Background: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features.

    Aims: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization. Read More

    Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from authors.
    Br J Dermatol 2017 Sep 10. Epub 2017 Sep 10.
    Department of Dermatology, Venerology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University, Bochum, Germany.
    We thank the authors Lewis, Kim, and Duvic, for their reaction to our article. The increasingly personalised medicine should also take into account individual tumour entities and their inter-individual pathways. Therefore, we can only welcome and sustain the comments. Read More

    Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.
    Br J Dermatol 2017 Sep 10. Epub 2017 Sep 10.
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Stranzenbach et al. propose alternate dosing regimens of brentuximab vedotin (BV) for CD30+ cutaneous T-cell lymphomas (CTCLs) such as mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL).(1) They emphasize that lower doses or less frequent dosing schedules for CTCL may be equally effective while limiting adverse events. Read More

    Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    Blood Cancer J 2017 Sep 8;7(9):e603. Epub 2017 Sep 8.
    Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
    CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Read More

    Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations.
    Int J Womens Dermatol 2017 Sep 11;3(3):140-144. Epub 2017 Jul 11.
    Department of Dermatology, University of Connecticut Health Center, Farmington, CT.
    One newly recognized form of T-cell lymphoma is breast implant-associated anaplastic large cell lymphoma (biALCL), which appears in close proximity to breast implants. The number of reported cases of biALCL is increasing and warrants careful attention by clinicians to more effectively diagnose and treat affected individuals. As pertinent to dermatologists, the objective of this paper is to present the associated cutaneous features of this clinical entity along with the pathogenesis, management, and clinical outcomes. Read More

    Monoclonal antibodies against cutaneous T-cell lymphomas.
    Expert Opin Biol Ther 2017 Dec 28;17(12):1503-1510. Epub 2017 Aug 28.
    a Unit of Dermatology, Department of Medicine , University of Padua , Padua , Italy.
    Introduction: Cutaneous T-cell lymphomas (CTCLs) comprise of a group of rare and heterogeneous skin lymphoproliferative disorders derived from skin resident T cells. Treatment of CTCLs is based on skin-directed approaches and/or systemic therapies. Advanced CTCLs are difficult to treat with the currently available treatments as they generally fail to obtain prolonged clinical remission. Read More

    Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Future Oncol 2017 Nov 14;13(27):2405-2411. Epub 2017 Aug 14.
    Dermatology - University Hospitals Birmingham NHS Foundation Trust, University Hospital Birmingham, Birmingham, B15 2TH, UK.
    CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Read More

    Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data.
    Int J Dermatol 2017 Dec 1;56(12):1400-1405. Epub 2017 Aug 1.
    Department of Dermatology, University of Texas Southwestern, Dallas, TX, USA.
    Background: The utility of brentuximab vedotin (BV) in CD30(+) systemic lymphomas is established, however evidence for treating primary cutaneous lymphoma remains limited. This study aimed to evaluate BV in treating CD30(+) transformed mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL).

    Methods: A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid-MEDLINE(®) and PubMed databases. Read More

    Anaplastic large cell lymphoma: A great mimic on cytology.
    J Cytol 2017 Jul-Sep;34(3):165-167
    Department of Pathology, Seth GS Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India.
    Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma, accounting for <5% of non-Hodgkin's lymphoma. Cutaneous involvement can be primary or secondary arising in systemic ALCL. The diagnostic feature in both is the presence of pleomorphic, CD30 positive hallmark cells. Read More

    Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Ann Diagn Pathol 2017 Jun 10;28:54-59. Epub 2017 Feb 10.
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address:
    Background: Negative immunoregulatory checkpoints impede effective immune responses to tumor and reduce the action of anticancer agents. One such example is programmed death marker-1 (PD-1), an inhibitory signaling receptor expressed on activated and regulatory T-cells. PD-1 expression was reported in a few reports, but the expression profile of PD-1 and mycosis fungoides (MF) remains largely to be characterized. Read More

    Myxoid variant of primary cutaneous anaplastic large cell lymphoma: First 2 cases.
    J Cutan Pathol 2017 Sep 18;44(9):772-775. Epub 2017 Jul 18.
    Department of Dermatology, Los Angeles Medical Center (LAMC), Southern California Kaiser Permanente, Los Angeles, California.
    Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell non-Hodgkin lymphoma with 2 main clinical presentations: primary cutaneous ALCL (pcALCL) and systemic ALCL (sALCL). While rare cases of myxoid sALCL have been reported, there are no previous cases of myxoid pcALCL reported. We present 2 unusual cases of pcALCL showing prominent collections of dermal mucin closely intermingling with the anaplastic lymphocytes. Read More

    Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study.
    J Cutan Med Surg 2017 Nov/Dec;21(6):507-512. Epub 2017 Jun 14.
    1 Division of Dermatology, University of Toronto, Toronto, ON, Canada.
    Background: Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. Although considered a benign disease, lymphomatoid papulosis has been associated potentially with an increased risk of secondary hematolymphoid malignancies.

    Objective: The aim of this study was to assess the clinical characteristics and histologic subtypes of lymphomatoid papulosis, identify the prevalence and types of secondary hematolymphoid malignancies, and determine the potential risk factors for development of these hematolymphoid malignancies. Read More

    Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
    Lancet 2017 Aug 7;390(10094):555-566. Epub 2017 Jun 7.
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Background: Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. Read More

    Primary Cutaneous Small Cell Variant of Anaplastic Large Cell Lymphoma: A Case Series and Review of the Literature.
    Am J Dermatopathol 2017 May 22. Epub 2017 May 22.
    *Professor of Pathology, Pathologist and Dermatopathologist, Director of Dermatopathology Division, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY; †Dermatopathology Fellow, Memorial Sloan Kettering Cancer Center/Weill Cornell Medicine, New York, NY; and ‡Assistant Professor of Clinical Dermatology, Department of Dermatology, UCDAVIS Health Center, Sacramento, CA.
    Primary cutaneous anaplastic large cell lymphoma (ALCL), similar to systemic ALCL, has as its histomorphologic hallmarks cohesive sheets of large lymphoid cells expressing CD30. Several morphologic variants of systemic ALCL have been reported, including the common (classic) type, lymphohistiocytic, and small cell variants. The small cell variant of ALCL is characterized by a predominant cytomorphology which is unexpected for ALCL, being in the context of a small- to medium-sized hyperchromatic atypical lymphocyte. Read More

    Lymphomatoid papulosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma: 3 cases.
    Br J Dermatol 2017 Jun 1. Epub 2017 Jun 1.
    Department of Dermatology, AP-HP, St Louis Hospital, Paris 7 University, Paris, France.
    Lymphomatoid papulosis (LyP) is considered as an indolent CD30+ lymphoproliferative cutaneous disorder. (1,2) Nevertheless, 10%-20% up to 50% of patients with LyP have coexistent lymphoma. (1, 3-7) The most frequently associated malignancies are mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, or Hodgkin's disease. Read More

    Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
    J Cutan Pathol 2017 Aug 13;44(8):703-712. Epub 2017 Jun 13.
    Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
    CD8-positive, CD30-positive cutaneous lymphoproliferative disorders constitute a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma (ALCL), mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma and cutaneous peripheral T-cell lymphoma. These entities share overlapping clinical, histopathologic and immunophenotypic features, presenting both a clinical and pathological diagnostic challenge. Presented here is a 73-year-old man with a disseminated, indolent CD30+, CD8+ cutaneous lymphoproliferative disorder with overlapping clinical and histopathological features of both mycosis fungoides and primary cutaneous ALCL, as well as features of lymphomatoid papulosis. Read More

    Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.
    Crit Rev Oncol Hematol 2017 May 27;113:8-17. Epub 2017 Feb 27.
    Hematology, Oncology, Blood & Marrow Transplantation, Department of Medicine, University of Arizona, Tucson, AZ, 85721, United States.
    Background: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. Read More

    Primary cutaneous anaplastic large cell lymphoma.
    J Cutan Pathol 2017 Jun 25;44(6):570-577. Epub 2017 Apr 25.
    Department of Pathology, Stanford University School of Medicine, Stanford, California.
    Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease. CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms. Read More

    CD30(+) Lymphoproliferative Disorders of the Skin.
    Hematol Oncol Clin North Am 2017 Apr;31(2):317-334
    Department of Dermatology, The Center for Cutaneous Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address:
    Primary cutaneous CD30(+) lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. Read More

    Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema.
    J Cutan Pathol 2017 Mar 23. Epub 2017 Mar 23.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
    Chronic lymphedema predisposes to develop malignant cutaneous tumors, including angiosarcoma, Kaposi's sarcoma and B-cell lymphoma. T-cell malignancy has rarely been associated with chronic lymph stasis. Here, we report a case of primary cutaneous anaplastic large cell lymphoma (pcALCL) with lymphatic spread associated with chronic lymphedema. Read More

    Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report.
    Dermatol Pract Concept 2017 Jan 31;7(1):59-61. Epub 2017 Jan 31.
    Second University of Naples, Department of Dermatology, Naples, Italy.
    Primary cutaneous CD 30 (+) anaplastic large cell lymphoma (PCALCL) is a rare and indolent type of cutaneous T cell lymphoma, which usually presents as an asymptomatic solitary firm nodule that rapidly grows and often ulcerates without any systemic involvement. A 64-year-old female presented to our outpatient clinic with a one-year history of multiple pink nodular lesions on the chest, back and gluteal regions. Dermoscopic examination of the nodular lesions revealed pink-to-yellow structureless areas and arborizing-to-polymorphous vessels. Read More

    CD30-positive cutaneous lymphoma: report of four cases with an emphasis on clinicopathological correlations.
    An Bras Dermatol 2017 Jan-Feb;92(1):86-91
    Hospital Federal de Bonsucesso - Bonsucesso (RJ), Brazil.
    The classification of cutaneous lymphomas is multidisciplinary and requires the correlation between clinical, histopathological, immunohistochemical, and molecular diagnostic elements. In this article, we present four different cases of CD30-positive T-cell lymphoma with cutaneous manifestations. We compare cases with definitive diagnosis of papulosis lymphomatoid type C, primary cutaneous anaplastic large T-cell lymphoma, systemic anaplastic large T-cell lymphoma with secondary skin involvement, and mycosis fungoides with large cell transformation, highlighting the importance of clinicopathological correlation to classify these cases. Read More

    Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.
    Hum Pathol 2017 Jun 30;64:19-27. Epub 2017 Jan 30.
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905. Electronic address:
    Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas that bear chromosomal rearrangements of the TP53 homologue TP63 in a subset of cases that demonstrate aggressive clinical behavior. In the present study, we examined the relationship between p63 protein expression by immunohistochemistry and the results of fluorescence in situ hybridization using TP63 probes in 116 ALCLs. We also determined the relative expression of full-length TAp63 and truncated ΔNp63 isoforms (eg, p40) in ALCL cell lines and a subset of clinical cases. Read More

    A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Semin Diagn Pathol 2017 Jan 29;34(1):22-35. Epub 2016 Nov 29.
    Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:
    Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

    Cutaneous lymphoma: Kids are not just little people.
    Clin Dermatol 2016 Nov - Dec;34(6):749-759. Epub 2016 Jul 10.
    Department of Dermatology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030.
    Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous lymphoma in childhood is rare, but it can present as early as the first decade of life. In both adults and children, the diagnosis of cutaneous lymphoma can be challenging because inflammatory dermatoses can mimic CTCL both clinically and histologically. Read More

    Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Expert Rev Hematol 2017 Jan 21;10(1):29-37. Epub 2016 Dec 21.
    a Hematology & Oncology , University of Alabama at Birmingham , Birmingham , AL , USA.
    Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Read More

    Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate.
    Cutis 2016 Oct;98(4):253-256
    Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
    Primary cutaneous anaplastic large-cell lymphoma (pcALCL) is part of a spectrum of CD30+ primary cutaneous lymphoproliferative disorders (pcLPDs) that also includes lymphomatoid papulosis (LyP). Localized radiotherapy at doses of 34 to 44 Gy is first-line treatment of pcALCL, but the use of low-dose radiotherapy for pcALCL has not been reported. We present the case of a patient with a history of pcALCL/LyP who was treated with low-dose radiotherapy while on oral low-dose methotrexate (MTX) once weekly. Read More

    Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience.
    Br J Haematol 2017 Jan 21;176(2):234-240. Epub 2016 Oct 21.
    Department of Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
    Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare CD30(+) lymphoproliferative disorder with excellent outcomes reported despite frequent cutaneous relapses. Limited information exists on the development of systemic lymphoma. The British Columbia Cancer Agency (BCCA) Lymphoid Cancer Database was searched to identify all adults diagnosed with PCALCL from 1993 to 2013. Read More

    Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
    J Cutan Pathol 2016 Nov 30;43(11):963-973. Epub 2016 Aug 30.
    1st Department of Pathology and Experimental Cancer Research Institute, Semmelweis University, Budapest, Hungary.
    Lymphomatoid papulosis (LyP) belongs to CD30+ lymphoproliferative disorders with indolent clinical course. Classic histological subtypes, A, B and C are characterized by the CD4+ phenotype, while CD8+ variants, most commonly classified as type D, were reported in recent years. We present 14 cases of CD8+ LyP. Read More

    CD30+ lymphoproliferative disorder with spindle-cell morphology.
    J Cutan Pathol 2016 Nov 26;43(11):1041-1044. Epub 2016 Aug 26.
    Department of Pathology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
    Lymphomatoid papulosis (LyP) is classified as a CD30+ primary cutaneous lymphoproliferative disease. The phenotypic variability along the spectrum of CD30+ lymphoproliferative diseases is highlighted by the distinct histologic subtypes of LyP types A, B, C, and the more recently described types D, E, and F. We report the case of an elderly woman with a clinical presentation and histopathologic findings consistent with LyP, whose atypical CD30+ infiltrate uniquely demonstrated a spindle-cell morphology. Read More

    Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Anticancer Agents Med Chem 2017 ;17(7):886-895
    Division of Hematology, University of Siena, Siena, Italy.
    The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target. Since unconjugated anti-CD30 antibody (SGN-30) demonstrated limited clinical activity, researchers' effort aimed to create an antibody-drug conjugate (ADC), leading to discovery of SGN-35 (brentuximab vedotin), in which an anti-CD30 antibody is linked to the antimitotic agent monomethyl auristatin E (MMAE). In the first phase I study in CD30+ hematologic malignancies (the majority of patients with HL), the maximum tolerated dose was fixed respectively at 1. Read More

    Synchronous Occurrence of Primary Cutaneous Anaplastic Large Cell Lymphoma and Squamous Cell Carcinoma.
    Ann Dermatol 2016 Aug 26;28(4):491-4. Epub 2016 Jul 26.
    Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    CD30+ lymphoproliferative disorders (LPD) represent a spectrum of T-cell lymphoma including lymphomatoid papulosis and anaplastic large cell lymphoma (ALCL). Epidermis overlying cutaneous CD30+ LPD often shows epidermal hyperplasia, hyperkeratosis, crusting, and ulceration and it is difficult to distinguish from carcinoma such as keratoacanthoma (KA) or squamous cell carcinoma (SCC). Several cases of pseudocarcinomatous hyperplasia mimicking KA or SCC in CD30+ LPD have been reported. Read More

    Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation.
    Diagn Cytopathol 2017 Jan 29;45(1):51-54. Epub 2016 Jul 29.
    Department of Cytology and Cytogenetic, University Hospital Merkur, Zagreb, Croatia.
    ALK positive anaplastic large cell lymphoma is a T-cell lymphoma usually occurring in children and young adults. It frequently involves lymph nodes and extranodal sites and is associated with favorable prognosis. A 20-year old man was admitted for painful mass in the left axilla with overlying skin redness. Read More

    New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Expert Rev Hematol 2016 Aug 14;9(8):767-80. Epub 2016 Jul 14.
    a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
    Introduction: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients.

    Areas Covered: Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Read More

    Loss of CD30 Expression in Anaplastic Large Cell Lymphoma Following Brentuximab Therapy.
    J Drugs Dermatol 2016 Jul;15(7):894-5
    Monoclonal antibody therapy is a new innovation in cancer therapy. Binding of monoclonal antibodies to tumor cells facilitates their destruction by the immune system. Tumor cells with mutated target antigens may escape detection by monoclonal antibodies and exhibit a selective growth advantage. Read More

    Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection.
    Infect Agent Cancer 2016 5;11:31. Epub 2016 Jul 5.
    Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara, Ferrara, Italy.
    Background: We have previously reported the case of an immunocompetent female patient with a primary cutaneous CD30+ anaplastic large-cell lymphoma (PCALCL) located on her upper right eyelid characterized by the presence of a concurrent active infection by C. pneumoniae and Human herpesvirus 8 (HHV8). This finding suggested for the first time a possible association of C. Read More

    Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review.
    Am J Blood Res 2016 18;6(1):1-5. Epub 2016 May 18.
    Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center Louisville, Kentucky, USA.
    Methotrexate (MTX) is a commonly used anti-metabolite agent. Increased risk of lymphoproliferative disorders (LPD) in patients with rheumatoid arthritis (RA) has been documented with the prolonged use of immunosuppressive medications such as MTX. This is thought to be the result of immune dysregulation and/or chronic immune stimulation. Read More

    CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy.
    Ann Dermatol 2016 Jun 25;28(3):371-4. Epub 2016 May 25.
    Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea.
    Anaplastic large-cell lymphoma (ALCL) is a CD30-positive T-cell/null-cell lymphoma that is clinically classified into either primary cutaneous ALCL or systemic ALCL (S-ALCL) sub-types. Because 90% of childhood S-ALCL cases are anaplastic lymphoma kinase (ALK)-positive, there is a lack of data on ALK-negative S-ALCL cases among pediatric patients. Herein, we report a rare case of ALK-negative S-ALCL in a 9-year-old Korean boy who initially presented with itchy erythematous maculopapules and an erosive nodule on the trunk area. Read More

    Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler 2016 Dec 26;22(14):1888-1890. Epub 2016 Apr 26.
    Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany.
    Background: The appearance of solid tumors und lymphomas during treatment with fingolimod was observed in studies and has been described in case reports.

    Objective: To report a case of primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis (MS) with fingolimod.

    Methods: Case study. Read More

    Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages.
    J Cutan Pathol 2016 Jul 8;43(7):579-88. Epub 2016 May 8.
    Kempf and Pfaltz Histologische Diagnostik, Zürich, Switzerland.
    Background: The tumor microenvironment is essential for tumor survival, growth and progression. There are only a few studies on the tumor microenvironment in cutaneous CD30-positive lymphoproliferative disorders.

    Methods: We assessed the composition of the tumor microenvironment using immunohistochemistry studies in skin biopsies from cases diagnosed with lymphomatoid papulosis (LyP: 18 specimens), primary cutaneous anaplastic large-cell lymphoma (PC-ALCL: 8 specimens), and reactive diseases harboring CD30-positive cells (18 specimens). Read More

    KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Br J Dermatol 2016 Aug 13;175(2):325-33. Epub 2016 Jul 13.
    Université Paris-Diderot, Sorbonne Paris Cité, Paris, 75010, France.
    Background: KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome. Anti-KIR3DL2 targeted antibody therapy has shown potent activity in preclinical models for these diseases.

    Objectives: To examine the expression of KIR3DL2 and its potential use as a therapeutic target in patients with primary cutaneous anaplastic large-cell lymphoma (pcALCL), the most aggressive cutaneous CD30(+) lymphoproliferative disease. Read More

    A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
    Am J Dermatopathol 2016 May;38(5):388-92
    *Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; †Department of Dermatology, Mayo Clinic, Rochester, MN, Dr. Cohen is now affiliated with the Department of Pathology and Immunology, Baylor College of Medicine, and Department of Pathology, Michael E. DeBakey Veterans Affairs Hospital, Houston, TX (As of/After July 1, 2015); ‡Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN; and §Departments of Laboratory Medicine and Pathology, and Dermatology, Mayo Clinic, Rochester, MN.
    CD30-positive cutaneous lymphoproliferative disorders, a group of T-cell neoplasms, including lymphomatoid papulosis (LyP) and cutaneous anaplastic large cell lymphoma, require careful clinicopathologic correlation for diagnosis. An association between LyP and the development of a second hematolymphoid malignancy has been established in the literature. LyP has also been reported with systemic amyloidosis, but no such reports have documented coexisting cutaneous amyloid deposition with LyP to our knowledge. Read More

    Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
    Aesthet Surg J 2016 Jul 15;36(7):773-81. Epub 2016 Mar 15.
    Dr Kadin is a Professor of Dermatology, Boston University School of Medicine, Boston, MA; and a Staff Physician, Roger Williams Medical Center, Providence, RI. Dr Deva is an Associate Professor of Cosmetic, Plastic, and Reconstructive Surgery, Macquarie University, NSW, Australia. Ms Xu is a Research Assistant, Dr Morgan is Director of the Research Core Facility, and Dr Khare is Director of the Cancer Immunotherapy and Gene Therapy Facility, Roger Williams Medical Center, Providence, RI. Dr MacLeod is Director of Cytogenetics at the Leibniz Institute, DSMZ - German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany. Dr Van Natta is an Associate Clinical Professor, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN. Dr Adams is an Associate Clinical Professor, Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX. Dr Brody is Professor Emeritus in the Division of Plastic Surgery, and Dr Epstein is a Professor of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA.
    Almost 200 women worldwide have been diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The unique location and specific lymphoma type strongly suggest an etio-pathologic link between breast implants and BIA-ALCL. It is postulated that chronic inflammation via bacterial infection may be an etiological factor. Read More

    Primary cutaneous anaplastic large-cell lymphoma: a case report.
    Dermatol Ther 2016 Jul 11;29(4):224-7. Epub 2016 Mar 11.
    Department of dermatology, Nan Fang Hospital, Guangzhou, China.
    Primary cutaneous anaplastic large-cell lymphoma (PCALCL) is a part of the spectrum of CD30+ lymphoproliferative cutaneous processes. The characteristics include single or multifocal nodules that ulcerate as skin lesion, slow disease progression, autoregressive, and recurrent in few years. The present study report the case of a 16-year-old boy presenting PCALCL with single nodules, ulcer, keloid, and scab in his right-side face. Read More

    Skin involvement as the first manifestation of breast implant-associated anaplastic large cell lymphoma.
    J Cutan Pathol 2016 Jul 5;43(7):602-608. Epub 2016 Apr 5.
    Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
    Breast implant-associated anaplastic large cell lymphoma (ALCL) is a newly described clinical and pathologic entity that typically presents as seroma in the fibrous scar around the implant. Less frequently, it presents as a solid peri-implant mass, and there have been no reports to date of cutaneous lesions as the presenting manifestation. We report the case of a 56-year-old woman with a history of bilateral breast reconstruction following breast cancer of the right breast who consulted with several papules on the right breast suggestive of metastasis. Read More

    1 OF 11